**RADIOPHARMACEUTICALS AND THEIR THERAPEUTIC APPLICATIONS**

**L. Karpagavalli1\*, D. Bharathi2**, **A.S. Durga Shree3, Prince Shawlin Sharwan3, S. Keerthana3, K. Krishnakumar3, Hemalatha K4**

1\*Department of Pharmaceutics, Jaya College of Pharmacy, Thiruninravur, Chennai-602024, Tamil Nadu, India

 2 Department of Pharmaceutical chemistry, Jaya College of Pharmacy, Thiruninravur, Chennai-602024, Tamil Nadu, India

3Jaya College of Pharmacy, Thiruninravur, Chennai-602024, Tamil Nadu, India

4Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Thandalam, Chennai, Tamil Nadu-602105, India

**Abstract**

A radio processor is a drug object or drug that can cause the impulsive pride of non-constant nuclei accompanying fallout or photons discharged for research, condition, situation, and referring to practices or policies that do not negatively affect the environment requests. Additionally, radio processors serve as radiocarbon emitters with sufferers, so admitting for the disease of biochemical, microscopic, corporeal, and bodily deformities in victims. Additionally, healing radioprotection of radio protectors may be accomplished inside through discriminating effect on particular anomalous containers and tools. For example, iodine-131 is second hand as a healing radio protective radio protector in subjects accompanying hypothyroidism. Furthermore, in research, radioprotection is administered accompanying radioprotection utilizing narrow amounts of radiolabelling wealth, other than demonstrative requests, but to consider the metabolites, biography-dispersive, pharmacodynamic and pharmacokinetics of few drugs in their nonradioactive forms. This phase focuses generally on the development, surroundings, drug, analyst, healing, research, and radioprotection uses of radioprotection.

**Keywords**: Radio processor, Radiocarbon, Radioprotection, Radiolabelling, Radio protectors

**Introduction**

 A radionuclide-holding drug commodity is a radiopharmaceutical. The majority of radionuclides in nuclear medicine are second hand for demonstrative purposes, but few radionuclides are also used to treat human afflictions. Radionuclides fastened to organic particles are capable of point or direct at a goal distinguishing means, tissues, or containers in the human body. The plurality of radiopharmaceutical commodity are second hand for healing and demonstrative purposes. They are usually executed only late or constantly various times and hold only narrow quantities of the alive meanings attached to the radionuclide to allow scintigraphic representations or biodistribution.[1] They have a short material half existence, meaning they are removed from the carcass and have an direct half growth nearly equal to the test occasion to prevent post-uncovering.

Major contrivances used for the situation of affliction and dysfunctions but too beneficially understanding of human diseases and the incident of productive situation alternatives, for example engaged of central nervous system. There is concern about ongoing influential progress engaged of nuclear cure, that is had connection with the happening of novel radioprotects and the efficient result of radioprotectors. Various advances have existed fashioned engaged of radopharmaceuticals, from the development, result and request of demonstrative, healing and theranostic radiosotopes and radioprotectants. Currently, radioprotectant therapy is executed intravenously or locoreginally and situation preparation has happened executed as chemotherapy, accompanying the endeavor executed being established or based on the patient’s physique pressure or BSA (Body Surface Area). The most prevailing radiosotope second hand in diagnostic basic cure (NMD) is technetium (99m) that maybe attached to many distinguishing particles and maybe used to determine many ailments, including few types of cancers.

 Nuclear medicine processes are working in the disease and treatment of sure ailments. These processes include the use of radioactive matters famous as radioprotectants. Common ailments that are considered with a basic cure process involve thyroid affliction, lymphomas and bone pain guide sure forms of tumor. One of ultimate recent advances in radiology, Varian Edge, is worthy medicating a cyst from a sort of angles with exact veracity and in a smaller amount momentary than traditional fallout medicine. This science, that is established Hybrid Molecular Imaging (HMI) and the use of accompanying Radioprotectants, proper expected well profitable in value located healthcare, as it specifies clinicians accompanying first-rate images and exact early disease and arranging.[2] According to Bibault, by 2030, all radiotherapy is inclined be automated, personalised and hypofracted, and FLASH will be the chief novelty engaged.

### **Mechanism and biological effects**

The mechanism of action for Radiopharmaceutical therapy (RPT) is radiation-induced killing of cells. Investigation into the effects of radiation on tissues and tumours began soon after the discovery of radiation and radioactivity. RPT has the benefit of drawing on the substantial knowledge base of radiotherapy. However, RPT differs from radiotherapy, and it is important to understand how those elements unique to RPT influence therapy.

The biological effects of a given absorbed dose for a tumour depend on the rate at which the dose is delivered. A dose of 30 [Gy](https://www.nature.com/articles/s41573-020-0073-9%22%20%5Cl%20%22Glos5) delivered to a tumour over a period of many weeks at a dose rate that is exponentially decreasing, as is typically the case with RPT, will have a very different effect from that of the same amount delivered at the much higher dose rates used in radiotherapy (for example, daily, 2-Gy fractions over 15 days). The difference in biological outcome will depend on the biological repair and radiosensitivity properties of the tumour. Dose-rate considerations also apply to normal organs. [3,4,5]

Another fundamental distinguishing feature important for understanding this treatment modality is the diminishing curative potential with reduced target cell number (Fig. [1](https://www.nature.com/articles/s41573-020-0073-9#Fig1)). In radiotherapy the probability of killing all cells for a given absorbed dose increases as the number of target cells decreases — fewer cells to kill for a given radiation absorbed dose increases the chance that all of the cells will be killed. By contrast, fewer cells do not translate into a greater tumour control probability in RPT. This is because the radiation is not delivered uniformly to all cells. If the emitted radiation originates from a radionuclide on the surface of tumour cells, fewer cells leads to a smaller fraction of the emitted energy being deposited into the targeted cells[14](https://www.nature.com/articles/s41573-020-0073-9#ref-CR14). This is balanced, in part, by the greater concentration that may be achieved in smaller clusters of cells relative to large measurable tumours.[6]

## **RPT agents in use and in clinical development**

A number of RPT agents are currently on the market, with many more in development (Table [2](https://www.nature.com/articles/s41573-020-0073-9#Tab2)). These include four β-particle and five α-particle emitters. Lead-212 decays to bismuth-212 and is used as a means to deliver 212Bi, an α-emitter, without being constrained by its 1-hour half-life. The interest in α-emitters reflects a potential growth area in RPT. Other RPT agents in addition are in preclinical development.

RPT can involve the direct delivery of the radioactive element itself. A wide variety of ‘delivery vehicles’ have also been used for RPT (Fig.1), including small molecules that incorporate the radionuclide. Radiolabelled peptides and antibodies make up the majority of RPT agents investigated clinically.[7,8,9] Liposomal or nanoconstruct delivery approaches are being investigated preclinically, but these have not yet been tested in human trials. Glass and resin microspheres are relatively well established; these are used in the treatment of hepatocellular carcinoma or hepatic metastases of colorectal cancer and are administered via the hepatic artery.[10]



**Fig. 1: Basic RPT constructs used for radiation delivery.**

**The various radiopharmaceutical therapy (RPT) constructs that have been used to deliver radiation are illustrated: radioactive element (part a); small molecule (part b); peptide (part c); antibody (part d); nanoconstruct (part e); microsphere (part f).**

 Different RPT constructs retain different amounts in the tumour, but it is difficult to generalize this. Antibody mediated delivery is bivalent, with long retention in general, but with a longer circulating half-life for antibodies, resulting in greater normal organ, especially haematologic, toxicity. Small molecules and peptides, on the other hand, have the advantage of fast targeting and clearance but tend to have shorter tumour retention in general. In all cases, if an agent is internalized, and the target radionuclide is intracellularly retained, the target retention will be very long in comparison to the clearance kinetics for the agent. And in all cases, an engineered agent can be designed that optimizes tumour retention while also increasing clearance kinetics.[11]

**Radiopharmaceuticals for Infection Imaging**

 The pandemic COVID-19 has intensified the attention for diagnosis and treatment of infectious diseases. Nuclear medicine with its prevailing scintigraphic, single photon emission computer tomography (SPECT) and positron emission tomography (PET) imaging modalities are always playing a significant protagonist in diagnosis of infections and distinguishing them from the sterile inflammation. Along with the clinically offered radiopharmaceuticals more unambiguous imaging agents like radiolabeled antibiotics and antimicrobial peptides for bacterial imaging, radiolabeled anti-fungals for fungal infections imaging, radiolabeled pathogen-specific antibodies and molecular engineered concepts are in progress.

The conventional tools still extensively used in the clinic today are 111In-labeled leukocyte imaging for most indications, 67Ga for imaging of opportunistic infections, pulmonary inflammation and interstitial nephritis and 2-Deoxy-2-[18F]fluoroglucose ([18F]FDG) for spinal osteomyelitis, vasculitis, sarcoidosis, and fever of anonymous origin and for detecting cardiovascular infection.[12]

**Radiolabeled Antibiotics for Imaging Bacterial Infections**

Lots of antibiotics have been radiolabelled with 99mThc to make it easier to see in a pre-clinical model of infection. Salt (SN(+2)) is used as a reducing agent for 99mThc, which creates a [99mThc-O]-3+ core, plus a 99mThc-Carbon-Or-N]-2+ core. The carbonyl of 99mThc might be less sensitive to antibiotic molecules because it's smaller size. It's still reduced in size by radiometals and PET-emitting 68Ga, so it can still be used to label CIPRFLOXACIN with two different chelating agent 2,2′,2″,2‴(1,4, 7, 10-TETRAAZACYCLODODODECANE-1, 4,7, 10-tetrahydrocarbonamide-DOTA). Nevertheless, both chelating agents are quite bulky macrocycles indicating labeling antibiotics with radiometals could disturb the probe entering the bacterium, or restrict with the binding to the intracellular target.

 In order to avoid radiometrics, it is possible to use PET-enableable "organic" radionucleides, such as "13N" or "11C" or "18F", which do not interfere with an antibiotic's molecular structure due to their low atomic radius. A study was conducted to investigate the potential use of "organic" radiionuclides to radiolabel anti-TB chemotherapy drugs, such as "Isozid-inh", "RIF", and "PZA" with 11C, and to carry out a full body PET imaging study in baboons. Additionally, a study was conducted to assess the utility of "PEGylated Isoniazid Conjugates" for the PET imaging of these drugs, with the assumption that they could be used as long- circulating carriers for improved therapy of Tuberculosis.

Murine were used widely as the infection models in the pre-clinical studies of radiolabeled antibiotics, along with rabbits, since the immune system of rabbits is considered to be closer to human immune system. Staphylococcus aureus was used most often to induce infection in experimental animals, however Mycobaterium tuberculosis, Bacteroides fragilis and Dentamoeba fragilis, E. coli, Pseudomonas aeruginosa and Salmonella enterica were also utilized. Images not only depicted the localization of the radiolabeled antibiotics with SPECT or PET but also computed the biodistribution in addition to imaging. Studies conveyed retention of 99mTc-labeled isoniazid at the sites of M. tuberculosis infection in rabbits for 72 h.

The bio distribution results in mouse model indicated that accumulation of 99mTc-ofloxacin in the infected muscle reached target to non-target (T/NT) ratio of 2 at 4 h post injection though 68Ga-ciprofloxacin tested in rats infected with S. aureus demonstrated T/NT ratio of 3–6 at 2 h depending on the chelating agent used. In E. coli rabbit model the accumulation of 99mTc-metronidazole at 1 h post injection reached T/NT ratio of 5.57. Results were promising for the clinical translation of these relatively cheap radiopharmaceuticals.[13]

# **Neutron-Activatable Radioembolic Agent for Hepatic Radioembolization**

Radioembolization is a great option for treating advanced-stage liver cancers, but its use is limited due to its expensive nature. A study was done to create microspheres of Samarium Carbonate-PolyMethacrylate (PMA) [152Sm2[CO3]3-PMA], which can be used as neutron activatable radiolabeling microspheres for liver radioembolization. The developed microspheres emit both therapeutic and diagnostic gamma radiation, which can be used after post-procedure imaging. The microspheres were made from commercially available PMAs by in-situ formation of 152Sm[CO3][PMA] within the pores of PMAs. The researchers found that the microspheres had a higher retention rate of over 98% over 120 hours compared to the conventionally radiolabelled method of ~85%. The microspheres also had suitable physicochemical properties to be used as theragnostic agents for liver radionuclide radioembolization, with a high retention rate in human blood plasma of 153Sm.[14].

# **Radioimmune Imaging in Inflammatory Bowel Disease**

 Molecular information acquired by imaging with radiolabelled monoclonal antibodies can non-invasively afford, for planning of best treatment and for observing the therapeutic response in cancer and chronic inflammatory diseases. Based on a comparative study, between radiolabelled anti-α4β7 integrin or radiolabelled anti-TNFα mAb with unlabelled anti-α4β7 integrin or anti-TNFα mAb prediction of therapeutic outcome was evaluated for its use as in pre-therapy scan. The two developed radiopharmaceuticals were studied for the expression of therapeutic targets for inflammatory bowel diseases (IBD), to be used for therapy decision making. Both anti-α4β7 integrin and anti-TNFα mAbs were successfully radiolabelled with technetium-99m with high labelling efficiency and stability.[15] Dextran sulfate sodium (DSS)-induced colitis was used as a model for murine IBD and the bowel uptake of radiolabelled mAbs was evaluated ex vivo and in vivo by planar and SPECT/CT images. Immunohistochemistry (IHC) score (partial and global) were compared to bowel uptake in four different regions. For the evaluation of biomarker expression preceding to therapy, in initial IBD, another group of DSS-treated mice was injected with radiolabelled mAb on day 2 of DSS administration (to quantify the presence of the target in the bowel) and then injected with a single therapeutic dose of unlabelled anti-α4β7 integrin or anti-TNFα mAb.[16] Noble association was demonstrated between bowel uptake of radiolabelled mAb and immunohistochemistry (IHC) score, both in vivo and ex vivo compared with unlabelled α4β7 integrin and anti-TNFα that had an inverse correlation between the bowel uptake of radiolabelled mAb and the histological score after therapy, proving that only mice with high α4β7 integrin or TNFα expression will benefit of therapy with unlabelled mAb.,[17,18]

# **Radionuclide Therapy of 153Sm2O3-Loaded Polystyrene Microspheres**

Samarium-153-oxide-loaded polystyrene ([153Sm]Sm2O3-PS) microspheres by neutron-activation was studied as a potential theranostic agent for hepatic radioembolization. Sprague-Dawley (SD) rat model with liver cancer were assessed for therapeutic efficacy and diagnostic imaging capabilities. Roughly 37 MBq of [153Sm]Sm2O3-PS microspheres was injected by intra-tumoural injection for study group while control group received an intra-tumoural injection of 0.1 mL of saline solution.[19] Investigation of diagnostic imaging capabilities of the microspheres was done using single photon emission computed tomography/computed tomography (SPECT/CT) system. Ultrasound images of all rats in the study group showed no tumour signs compared to tumour volumes in control group. The SPECT/CT images clearly exhibited the location of [153Sm]Sm2O3-PS in the liver tumour of all rats at Day 5 post-injection. Additionally, the [153Sm]Sm2O3-PS microspheres were visible on the CT images and this had supplementary benefits of 153Sm as a CT contrast agent. Study revealed that the Neutron-activated [153Sm]Sm2O3-PS microspheres demonstrated excellent therapeutic and diagnostic imaging capabilities for theranostic treatment of liver cancer in a SD rat model. [20,21]

# Pharmaceutics 15 00536 g003 550

# **Figure 2. SPECT/CT images of a rat in the study group at Day 5 post-injection. Images displayed the location of 153Sm microspheres in the liver tumour**.

# **Functional PET Liver Imaging of Novel Radiotracers**

 Two new radiotracers (68Ga) and (TMOS-DAZA) are good for PET liver imaging. These tracers could be useful for measuring segmental liver function, gall tree imaging, and differentiating liver nodules because of their special liver uptake and bile excretion. In a study to look at complications that could happen early in the development of a GMP-compliant synthesis procedure and to test the tracer in a pre-clinical model, it was found that low radiolabelling yields were due to precursor instability at higher temperatures, so an optimized radiolabelling procedure was developed. The quality controls were in line with Ph.E.R. requirements and the results were compliant, but the method for determining 68Ga colloid was partially blocked due to a radioactive waste by-product. LogP showed that [68Ga] Ga-TEVO-DAZA (ethyloxy bearing) had more lipophilic properties than [68Ga Ga-TMOZ-DAZA. In an in vivo model, the liver uptake was higher for [68Ga]. Liver Tracer Build-Up in Dynamic in vivo PET Imaging Intravenous Activity Increases Gradually in First Hour P.I., Indicating Biliary Excess As [68Ga][TEoS][DAZA][68Ga][TMoS][DAZA] can be prepared in accordance with GMP guidance, transition into early clinical phase may be possible.[22]



**Figure 3. Structure of DEoS-DAZA and DMoS-DAZA (di-alkylated), respectively, and EoS-DAZA and MoS-DAZA (mono-alkylated), respectively, which are formed under acidic conditions. DEoS-DAZA and DMoS-DAZA are penta-dentate chelators that bind to 68Ga as well, thereby forming a radioactive impurity in the final product solutions.**

# **Radionuclide Therapy for Cancer Treatment**

 Although radiation therapy was first used in oncology almost a hundred years ago, its basic principle is still in use today, for example, in the form of RNT (Radionuclide Therapy) or TRT (Targeted Radionuclide Therapy). TRT has been shown to be effective in micro- and macro-metastasis and is beneficial due to its low dose, high-effectiveness, easy targeting, and treatment. An overview of the radiocompromise elements of a TRT, i.e. different types of radiocompromises, vectors, and chelators Highlights of TRT agent as therapeutic potential in various types of cancers: Breast cancer Metastatic bone pain Thyroid cancer Neuroendocrine neoplasms Prostate tumors Malignant lymphoma Brain tumors Hepatoid lymphoma Hepatocellular carcinoma.

 Nanoparticles made of iron oxide are used in a lot of medical settings because they're bio-compatible and can be broken down. This time, they were designed to treat cancer in a group of people who are positive for HER2 (her2-positive). The magnetic core of the nanoparticles was coated with gold-198, making them "core-shell" nanoparticles. Then, they were modified with a biopilot and a PEG-linker, as well as a mono-antibody. The bioconjugations of the nanoparticles were studied using a thermogram and iodine labeling. They were able to bind and internalize specific cancer cells (SKOV-3) and were small enough to be measured with a TEM (transmission electron microscopy). They showed great potential for use in in vivo studies, with the aim of developing a device that could be used in combination with radionuclides.[23]

# **Radionuclides in Targeted Therapy**

Nuclear medicine is now projected to be a subspecialty using targeted radionuclides. Previously, radionuclide treatment was limited to iodine-131 for thyroid disorders. Today, radiopharmacaceuticals are being combined with a vector to bind to a target with high specificity. Therapy should be as selective at the tumor level as possible while limiting the dose at the normal tissue level. Currently, focused on better understanding of cancer molecular mechanisms, the emergence of novel targeting agents (an antibody, peptide, and small molecule) and the availability of novel radionuclides, major advances in vectorized radiotherapy with better therapeutic effectiveness, radiation safety and personalised treatments have been developed. For example, targeting tumor microenvironment instead of cancer cells now seems particularly attractive. A number of radiopharmacological therapeutic targeting products have demonstrated clinical value in various types of tumors and are or will be approved and authorised for clinical use. Based on their clinical and commercial track record, research in this domain is accelerating, with the Clinical Pipeline emerging as a promising area.

 For decades, radioprotection drugs have been used to treat advanced prostate cancer. But recently, a new alpha emitter called Radium-223 has been a game-changer for the field, helping to extend survival in people with prostate cancer that has spread to other parts of the body. Now, with FDA approval, the development of a new beta-emitter called Lutetium-177 Lu-177 PSMA-617 has become even more important. Phase III trials are ongoing in patients with prostate cancer and other types of cancer, and the results could change the way we treat these diseases. Plus, phase I and II trials are still in the making, looking at combination therapies, radio-labeled antibodies, and new compounds. PSMA-targeted therapies using beta emitters like 177Lu and new alpha emitters like 225Actinium are still in the early stages of development, but it looks like they could be a big part of the treatment for advanced prostate cancer.[24,25]



 **Figure 4. Possible targets for targeted radionuclide therapy.**

#  **Lutetium-177 Dotatate for Neuroendocrine Tumours**

 Tumours caused by neuroendocrine cells, which are distributed throughout the body and responsible for producing and secreting hormones, are called neuroendocrine tumours. These tumours are found in different organs, including the gastrointestinal tract (GUT), pancreas (Pancreas), and lungs. Treatment is difficult because these tumours are slow-growing but can sometimes be fatal and metastasize to other areas of the body. Somatostatin (SSTR) receptors on the surface of the body’s neuroendocrine cells are over-expressed. These receptors bind to a specialised radiolabelled radionuclide called Lutetium Dotatate, which is preferentially absorbed by the neuroendocrine cells. This targeted approach delivers a high dose of gamma radiation directly to the site of the tumour, while also sparing healthy tissues by imitating somatostatin. This approach minimises the side effects that conventional radiation therapy can cause, such as collateral damage to healthy cells around the tumour site.[26]

**Radiopharmaceuticals cordial anti-tumor immunity**

 Tumor cells can be completely wiped out by the immune system's natural and adaptive defenses, but the immune system needs to be able to recognize danger signals on the tumor cells in order to do a good job of getting rid of them. It's possible that some cancer cells could get to a point where they start fighting with the immune system, but even in this state, the immune system can still keep them under control. Another way the immune system interacts with an emerging cancer is when uncontrolled tumor cells get away from the immune system, then start to grow slowly because they're not as immune as they should be, and the immune system creates a tumor microenvironment.

 Radiotherapy-induced immunogenicity (ICD) leads to the development of an anti-tumour immune response, which in turn leads to a decrease in cell death modalities susceptible to activating an immune response. The death process of irradiated tumor cells is characterized by an increase in regulation of immune-stimulating cell surface molecules, an expansion of the cell peptide pool, as well as the production of cytokines, also known as DAMPs. ICD after radiotherapy triggers the production of a multitude of mediators, referred to as DAMPs, in the extracellular environment. DAMPs are identified by macrophages, and DCs, which are activated by a variety of pathways, including Toll-like receptor (TLR) activation, and induce their maturation. DAMPs also facilitate the transmissibility of tumor antigen, and facilitate the release of cytokine-stimulating factors, such as IL-1β and IL-23, which activate the infiltration and chemotactic activity of immune effectors, such as NK cells and CD4+ T lymphocytes. Radiotherapy stimulates the induction of an acute inflammatory response in tumors by the regulation of a variety of cytokines. These cytokines include TNF-A (Tumour Necrosis Factor-Alpha), IL-4 (IL-6), IL-8 (IL-8), IL-1A (IL-1B), and IL-2 (IL-2C).[27]

**Conclusions**

Radiopharmaceuticals represent a major breakthrough for clinical medicine and bioinformatics, with remarkable advantages, such as rapid and non-invasive diagnostics and treatment of socially relevant diseases, such as inflammation and cancer, cardiovascular disorders, and neurodegenerative diseases. Rapid advances along the pathway of debt-of-pharmacokinetics-and-clearance required to afford an optimal dose and to screen the effectiveness of treatment, as well as personalized medicine through the delivery of novel therapeutics through targeted drug delivery, will bring greater specificity and selectiveness to patient care.

**References**

1. Iverson, Cheryl. Radiopharmaceuticals. Oxford University Press, ISBN 978-0-19-517633-9, 2007.
2. Wong C. H., Siah, K. W, Lo A. W. Estimation of clinical trial success rates and related parameters. Biostatistics. 20, 2018, 273–286.
3. Lin A. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci. Transl Med. 11, 2019, 8412.
4. Gill M. R, Falzone N, Du Y, Vallis K. A. Targeted radionuclide therapy in combined-modality regimens. Lancet Oncol. 18, 2017, 414–423.
5. Dolgin E. Radioactive drugs emerge from the shadows to storm the market. Nat. Biotechnol. 36, 2018, 1125–1127.
6. Wu A. M, Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Biotech. 23, 2005, 1137–1146.
7. Hu S. Z. Novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) for high-level targeting of xenografts. Cancer Res. 56, 1996, 3055–3061.
8. Wu A M. Tumor localization of anti-CEA single-chain improved targeting by non-covalent dimers. Immunotechnology. 2, 1996, 21–36.
9. Cheung N K V. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. J. Nucl. Med. 45, 2004, 867–877.
10. Boerman O C. Pretargeting of renal cell carcinoma for improved tumor Chang C H, Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol. Cancer Ther. 1, 2002, 553–563.
11. Front Med Lausanne. 9:819702. Published online 2022, doi: 10.3389/fmed.2022.819702.
12. Ekaterina Dadachova, Drauzio E N, Rangel. Highlights of the Latest Developments in Radiopharmaceuticals for Infection Imaging and Future Perspectives. Front Med Lausanne. 9: 2022; 819702.
13. Yin How Wong, Azahari Kasbollah Basri, Johan Jeet Abdullah, Chai Hong Yeong. Facile Preparation of Samarium Carbonate-Polymethacrylate Microspheres as a Neutron-Activatable Radioembolic Agent for Hepatic Radioembolization. Pharmaceutics. 15(3), 2023, 877.
14. Alberto Signore, Rita Bonfiglio , Michela Varani , Filippo Galli , Giuseppe Campagna, Manuel Desco. Radioimmune Imaging of α4β7 Integrin and TNFα for Diagnostic and Therapeutic Applications in Inflammatory Bowel Disease. Pharmaceutics. 15(3), 2023, 817.
15. Christian M, Giovanni, M, Torsten K, Mariangela A. Ultrasonography in inflammatory bowel disease. United Eur. Gastroenterol. J. 10, 2022, 225–232.
16. Elhag D.A, Kumar M, Saadaoui M, Akobeng A K, Al Mudahka F, Elawad M, Al Khodor S. Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response. Int. J. Mol. Sci. 23, 2022, 6966.
17. Yan G, Wang X, Fan Y, Lin J, Yan J, Wang L, Pan D, Xu Y, Yang M. Immuno-PET Imaging of TNF-α in Colitis Using 89Zr-DFO-infliximab. Mol. Pharm. 19, 2022, 3632–3639.
18. Hun Yee Tan, Yin How Wong, Azahari Kasbollah, Mohammad Nazri Md Shah. Evaluation of Therapeutic Efficacy and Imaging Capabilities of 153Sm2O3-Loaded Polystyrene Microspheres for Intra-Tumoural Radionuclide Therapy of Liver Cancer Using Sprague-Dawley Rat Model. Pharmaceutics. 15(3), 2023, 817.
19. Stella M, Braat A J A T, Van Rooij R, De Jong H W A M, Lam M G E H. Holmium-166 radioembolization Current status and future prospective. Cardiovasc. Interv. Radiol. 45, 2022, 1634–1645.
20. Tan H Y, Wong Y H, Kasbollah A, Shah M, Abdullah B J J, Perkins A C, Yeong CH. Development of neutron-activated samarium-153-loaded polystyrene microspheres as a potential theranostic agent for hepatic radioembolization. Nucl. Med. Commun. 2022, 99.
21. Julia Greiser, Thomas Winkens, Olga Perkas, Christian Kuehnel. Automated GMP Production and Preclinical Evaluation of [68Ga]Ga-TEoS-DAZA and [68Ga]Ga-TMoS-DAZA. Pharmaceutics. 14(12), 2022, 2695.
22. Michał Żuk, Rafał Podgórski, Anna Ruszczyńska, Tomasz Ciach. Multifunctional Nanoparticles Based on Iron Oxide and Gold-198 Designed for Magnetic Hyperthermia and Radionuclide Therapy as a Potential Tool for Combined HER2-Positive Cancer Treatment. Pharmaceutics. 14(8), 2022, 1680.
23. Nicolas Lepareur, Barthélémy Ramée, Marie Mougin-Degraef. Clinical Advances and Perspectives in Targeted Radionuclide Therapy. https://www.bioworld.com/radiopharmaceuticals.Pharmaceutics. 15(6), 2023, 1733.
24. Brian Ramnaraign, Oliver Sartor. PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials. The Oncologist, Volume 28, Issue 5, May 2023, 392–401.
25. Maqsood M, Tameez Ud Din A, Khan A H) Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review. Cureus.11(1): Jan 30, 2019, 10.7759/cureus.3986
26. Sun, Jiyuan Li, Zexuan Ding, Zhibo Liu. Radiopharmaceuticals heat anti-tumor immunity. Theranostics. 13(2): 2023, 767–786.
27. Goel M, Mishra M K, Kumar D. Recent advances in Targeted Radionuclide therapy for Cancer treatment. *Chemical Biology Letters*. *10*(3), 2023,544.